Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease

Marco Confalonieri, Elsa Mainardi, Rossana Della Porta, Sergio Bernorio, Luciano Gandola, Bianca Beghè, Antonio Spanevello

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background - Airways inflammation is a feature of chronic obstructive pulmonary disease (COPD), but the role of corticosteroids in the management of clinically stable patients has yet to be established. A randomised controlled study was carried out to investigate the effect of high dose inhaled beclomethasone dipropionate (BDP) administered for two months to patients with stable, smoking related COPD. Sputum induction was used to evaluate bronchial inflammation response. Methods - 34 patients (20 men and 14 women) were examined on three separate occasions. At the initial clinical assessment (visit 0), spirometry and blood gas analysis were performed. On visit 1 (within one week of visit 0) sputum induction was performed and each patient was randomised to receive either BDP 500 μg three times daily (treated group) or nothing (control group). After two months (visit 2), all patients underwent repeat clinical assessment, spirometry, and sputum induction. Results - There were no differences in sputum cell counts between the groups at baseline. After two months of treatment, induced sputum samples from patients in the treated group showed a reduction in both neutrophils (- 27%) and total cells (-42%) with respect to baseline, while the control group did not (neutrophils +9%, total cells +7%). Macrophages increased in the treated group but not in the control group. The mean final value of sputum neutrophils was 52% in the treated group and 73.3% in the control group (95% confidence interval (CI) -27.2 to -15.4). The mean final value of sputum macrophages was 35.8% in treated group and 19.3% in control group (95% CI 10.3 to 22.8). The differences between the treated and control groups for neutrophils (-21.3%), macrophages (+16.5%), and total cells (-65%) were significant. Spirometry and blood gas data did not change from baseline in either patient group. Conclusions - A two month course of treatment with high dose inhaled BDP reduces significantly neutrophil cell counts in patients with clinically stable, smoking related COPD. Further studies on the effectiveness of inhaled steroids in COPD are needed to confirm the clinical importance of this observation.

Original languageEnglish
Pages (from-to)583-585
Number of pages3
JournalThorax
Volume53
Issue number7
Publication statusPublished - 1998

Fingerprint

Chronic Obstructive Pulmonary Disease
Sputum
Adrenal Cortex Hormones
Inflammation
Neutrophils
Beclomethasone
Control Groups
Spirometry
Macrophages
Cell Count
Smoking
Confidence Intervals
Blood Gas Analysis
Gases
Steroids
Therapeutics

Keywords

  • Beclomethasone dipropionate
  • Chronic obstructive pulmonary disease
  • Induced sputum analysis
  • Neutrophils

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Confalonieri, M., Mainardi, E., Della Porta, R., Bernorio, S., Gandola, L., Beghè, B., & Spanevello, A. (1998). Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax, 53(7), 583-585.

Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. / Confalonieri, Marco; Mainardi, Elsa; Della Porta, Rossana; Bernorio, Sergio; Gandola, Luciano; Beghè, Bianca; Spanevello, Antonio.

In: Thorax, Vol. 53, No. 7, 1998, p. 583-585.

Research output: Contribution to journalArticle

Confalonieri, M, Mainardi, E, Della Porta, R, Bernorio, S, Gandola, L, Beghè, B & Spanevello, A 1998, 'Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease', Thorax, vol. 53, no. 7, pp. 583-585.
Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghè B et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax. 1998;53(7):583-585.
Confalonieri, Marco ; Mainardi, Elsa ; Della Porta, Rossana ; Bernorio, Sergio ; Gandola, Luciano ; Beghè, Bianca ; Spanevello, Antonio. / Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. In: Thorax. 1998 ; Vol. 53, No. 7. pp. 583-585.
@article{ba7f85b7e73e417fbf7a7198c8abdc5a,
title = "Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease",
abstract = "Background - Airways inflammation is a feature of chronic obstructive pulmonary disease (COPD), but the role of corticosteroids in the management of clinically stable patients has yet to be established. A randomised controlled study was carried out to investigate the effect of high dose inhaled beclomethasone dipropionate (BDP) administered for two months to patients with stable, smoking related COPD. Sputum induction was used to evaluate bronchial inflammation response. Methods - 34 patients (20 men and 14 women) were examined on three separate occasions. At the initial clinical assessment (visit 0), spirometry and blood gas analysis were performed. On visit 1 (within one week of visit 0) sputum induction was performed and each patient was randomised to receive either BDP 500 μg three times daily (treated group) or nothing (control group). After two months (visit 2), all patients underwent repeat clinical assessment, spirometry, and sputum induction. Results - There were no differences in sputum cell counts between the groups at baseline. After two months of treatment, induced sputum samples from patients in the treated group showed a reduction in both neutrophils (- 27{\%}) and total cells (-42{\%}) with respect to baseline, while the control group did not (neutrophils +9{\%}, total cells +7{\%}). Macrophages increased in the treated group but not in the control group. The mean final value of sputum neutrophils was 52{\%} in the treated group and 73.3{\%} in the control group (95{\%} confidence interval (CI) -27.2 to -15.4). The mean final value of sputum macrophages was 35.8{\%} in treated group and 19.3{\%} in control group (95{\%} CI 10.3 to 22.8). The differences between the treated and control groups for neutrophils (-21.3{\%}), macrophages (+16.5{\%}), and total cells (-65{\%}) were significant. Spirometry and blood gas data did not change from baseline in either patient group. Conclusions - A two month course of treatment with high dose inhaled BDP reduces significantly neutrophil cell counts in patients with clinically stable, smoking related COPD. Further studies on the effectiveness of inhaled steroids in COPD are needed to confirm the clinical importance of this observation.",
keywords = "Beclomethasone dipropionate, Chronic obstructive pulmonary disease, Induced sputum analysis, Neutrophils",
author = "Marco Confalonieri and Elsa Mainardi and {Della Porta}, Rossana and Sergio Bernorio and Luciano Gandola and Bianca Begh{\`e} and Antonio Spanevello",
year = "1998",
language = "English",
volume = "53",
pages = "583--585",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "7",

}

TY - JOUR

T1 - Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease

AU - Confalonieri, Marco

AU - Mainardi, Elsa

AU - Della Porta, Rossana

AU - Bernorio, Sergio

AU - Gandola, Luciano

AU - Beghè, Bianca

AU - Spanevello, Antonio

PY - 1998

Y1 - 1998

N2 - Background - Airways inflammation is a feature of chronic obstructive pulmonary disease (COPD), but the role of corticosteroids in the management of clinically stable patients has yet to be established. A randomised controlled study was carried out to investigate the effect of high dose inhaled beclomethasone dipropionate (BDP) administered for two months to patients with stable, smoking related COPD. Sputum induction was used to evaluate bronchial inflammation response. Methods - 34 patients (20 men and 14 women) were examined on three separate occasions. At the initial clinical assessment (visit 0), spirometry and blood gas analysis were performed. On visit 1 (within one week of visit 0) sputum induction was performed and each patient was randomised to receive either BDP 500 μg three times daily (treated group) or nothing (control group). After two months (visit 2), all patients underwent repeat clinical assessment, spirometry, and sputum induction. Results - There were no differences in sputum cell counts between the groups at baseline. After two months of treatment, induced sputum samples from patients in the treated group showed a reduction in both neutrophils (- 27%) and total cells (-42%) with respect to baseline, while the control group did not (neutrophils +9%, total cells +7%). Macrophages increased in the treated group but not in the control group. The mean final value of sputum neutrophils was 52% in the treated group and 73.3% in the control group (95% confidence interval (CI) -27.2 to -15.4). The mean final value of sputum macrophages was 35.8% in treated group and 19.3% in control group (95% CI 10.3 to 22.8). The differences between the treated and control groups for neutrophils (-21.3%), macrophages (+16.5%), and total cells (-65%) were significant. Spirometry and blood gas data did not change from baseline in either patient group. Conclusions - A two month course of treatment with high dose inhaled BDP reduces significantly neutrophil cell counts in patients with clinically stable, smoking related COPD. Further studies on the effectiveness of inhaled steroids in COPD are needed to confirm the clinical importance of this observation.

AB - Background - Airways inflammation is a feature of chronic obstructive pulmonary disease (COPD), but the role of corticosteroids in the management of clinically stable patients has yet to be established. A randomised controlled study was carried out to investigate the effect of high dose inhaled beclomethasone dipropionate (BDP) administered for two months to patients with stable, smoking related COPD. Sputum induction was used to evaluate bronchial inflammation response. Methods - 34 patients (20 men and 14 women) were examined on three separate occasions. At the initial clinical assessment (visit 0), spirometry and blood gas analysis were performed. On visit 1 (within one week of visit 0) sputum induction was performed and each patient was randomised to receive either BDP 500 μg three times daily (treated group) or nothing (control group). After two months (visit 2), all patients underwent repeat clinical assessment, spirometry, and sputum induction. Results - There were no differences in sputum cell counts between the groups at baseline. After two months of treatment, induced sputum samples from patients in the treated group showed a reduction in both neutrophils (- 27%) and total cells (-42%) with respect to baseline, while the control group did not (neutrophils +9%, total cells +7%). Macrophages increased in the treated group but not in the control group. The mean final value of sputum neutrophils was 52% in the treated group and 73.3% in the control group (95% confidence interval (CI) -27.2 to -15.4). The mean final value of sputum macrophages was 35.8% in treated group and 19.3% in control group (95% CI 10.3 to 22.8). The differences between the treated and control groups for neutrophils (-21.3%), macrophages (+16.5%), and total cells (-65%) were significant. Spirometry and blood gas data did not change from baseline in either patient group. Conclusions - A two month course of treatment with high dose inhaled BDP reduces significantly neutrophil cell counts in patients with clinically stable, smoking related COPD. Further studies on the effectiveness of inhaled steroids in COPD are needed to confirm the clinical importance of this observation.

KW - Beclomethasone dipropionate

KW - Chronic obstructive pulmonary disease

KW - Induced sputum analysis

KW - Neutrophils

UR - http://www.scopus.com/inward/record.url?scp=0031841422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031841422&partnerID=8YFLogxK

M3 - Article

C2 - 9797758

AN - SCOPUS:0031841422

VL - 53

SP - 583

EP - 585

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 7

ER -